Test Menu Category: Lung Cancer

Case Study

ALK Gene Copy and Amplification Frequency Increased in NSCLC Case Study

Personalized Medicine

Non-Small-Cell Lung Cancer
Non-small cell lung carcinoma (NSCLC) accounts for up to 80% of all lung cancers with an overall 5-year survival rate of 10% to 15%. Management of NSCLC requires a rational approach to reduce treatment cost and provide effective targeted drug therapy. Molecular biomarkers are associated with over 50% of cases of NSCLC, including EGFR (10-35%) and ALK mutations. Patients now benefit from the availability of several new drugs to treat advanced and metastatic NSCLC. Eligibility for these drugs is concurrent with companion diagnostic testing.


Lung Cancer Tests

ALK 2p23 rearrangement by FISH

BRAF Mutation Analysis by Next Generation Sequencing

Bronchoalveolar Lavage (CD3, CD4, CD8, CD16, CD45, CD4:CD8 ratio)

EGFR amplification (7p11.2) by FISH

EGFR Mutation Analysis by Next Generation Sequencing

KRAS Mutation Analysis by Next Generation Sequencing

Lung Cancer Panel by Next Generation Sequencing

Lung Markers by Immunohistochemistry (IHC)

PD-L1 by IHC

ROS1 6q22.1 rearrangement by FISH